TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29432077

Group type: EXPERIMENTAL
Intervention: DNX-2401 (Delta-24-RGD)
Number of subjects: 37
Study: 29432154

Group type: EXPERIMENTAL
Intervention: Moxetumomab pasudotox (Moxe)
Number of subjects: 0
Study: 29432378

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass with a more than 40% pressure drop below normal age-standardised mean arterial pressure for 19.5 minutes
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass with a more than 50% pressure drop for 5.4 minutes
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Maintaining perfusion pressure above 60% of normal age-standardised mean arterial pressure
Number of subjects: 72
Study: 29432402

Group type: EXPERIMENTAL
Intervention: Intraosseous access performance scale
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Team Average Performance Assessment Scale
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Behavioral Assessment Tool for leaders
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Clinical Teamwork Scale
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Self-reported stress
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Self-confidence
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Dissatisfaction
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Stress markers (salivary cortisol, heart rate, pNN50, low- and high-frequency ratio)
Number of subjects: 48
Study: 29432968

Group type: EXPERIMENTAL
Intervention: Text messaging intervention
Number of subjects: 0
Study: 29433525

Group type: EXPERIMENTAL
Intervention: Carvedilol-SR
Number of subjects: 320

Group type: COMPARATOR
Intervention: Carvedilol-IR
Number of subjects: 320
Study: 29433560

Group type: EXPERIMENTAL
Intervention: Insulin-treated T1DM patients
Number of subjects: 2348

Group type: EXPERIMENTAL
Intervention: Insulin-treated T2DM patients
Number of subjects: 2348
Study: 29433573

Group type: EXPERIMENTAL
Intervention: GH-treated patients (GH dose 0.30±0.16 mg/day for females and 0.25±0.10 mg/day for males)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Untreated GHD controls
Number of subjects: 106
Study: 29434012

Group type: EXPERIMENTAL
Intervention: I-STAND intervention (personal coaching + Jawbone UP band)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy living intervention (control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: I-STAND intervention
Number of subjects: 60
Study: 29434016

Group type: EXPERIMENTAL
Intervention: Text intervention (Coachtext)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Voice Assist intervention (MyCoach)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study: 29434460

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 29434547

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Active tDCS with high motivation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Motivation to quit (baseline and follow-up)
Number of subjects: 36
Study: 29435343

Group type: EXPERIMENTAL
Intervention: Machine learning algorithm (MLA) for severe sepsis prediction
Number of subjects: 142

Group type: COMPARATOR
Intervention: Current severe sepsis detector
Number of subjects: 142
Study: 29435359

Group type: EXPERIMENTAL
Intervention: Tofacitinib monotherapy (5 mg and 10 mg twice daily)
Number of subjects: 4967

Group type: EXPERIMENTAL
Intervention: Tofacitinib combination therapy (5 mg and 10 mg twice daily)
Number of subjects: 4967

Group type: EXPERIMENTAL
Intervention: Mono→combo switchers
Number of subjects: 4967

Group type: EXPERIMENTAL
Intervention: Combo→mono switchers
Number of subjects: 4967

Group type: EXPERIMENTAL
Intervention: Tofacitinib monotherapy and combination therapy
Number of subjects: 4967
Study: 29435360

Group type: EXPERIMENTAL
Intervention: Intravenous abatacept
Number of subjects: 2350
Study: 29435364

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secukinumab 75 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg and 75 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29435776

Group type: EXPERIMENTAL
Intervention: Anagliptin 100 mg orally twice per day
Number of subjects: 300

Group type: COMPARATOR
Intervention: Sitagliptin 50 mg orally once per day
Number of subjects: 300
Study: 29435872

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy with weekly paclitaxel (50 mg/m²) and carboplatin, radiation therapy (50.4 Gy/28 Fx or 61.2 Gy/34 Fx)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy with weekly paclitaxel and carboplatin
Number of subjects: 65
Study: 29436490

Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus deep brain stimulation
Number of subjects: 69
Study: 29437243

Group type: EXPERIMENTAL
Intervention: Melatonin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (Cigarette smoking without melatonin)
Number of subjects: 0
Study: 29437592

Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 132
Study: 29437593

Group type: EXPERIMENTAL
Intervention: Current immunosuppressive therapies for SR-aGVHD
Number of subjects: 0
Study: 29437596

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 12365
Study: 29437753

Group type: EXPERIMENTAL
Intervention: Circulating tumour DNA (ctDNA) detection after surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiplex assay based on circulating single-molecule amplification and resequencing technology (cSMART)
Number of subjects: 0
Study: 29437866

Group type: EXPERIMENTAL
Intervention: HIV diagnosis
Number of subjects: 640
Study: 29437935

Group type: EXPERIMENTAL
Intervention: Barrel vascular reconstruction device (Barrel VRD)
Number of subjects: 20
Study: 29437944

Group type: EXPERIMENTAL
Intervention: Lowest quartile of emphysema (LAA%)
Number of subjects: 1817

Group type: EXPERIMENTAL
Intervention: Highest quartile of emphysema (LAA%)
Number of subjects: 1817

Group type: EXPERIMENTAL
Intervention: Emphysema progression
Number of subjects: 1817
Study: 29438080

Group type: EXPERIMENTAL
Intervention: tPA-induced thrombolysis with recombinant DNAse 1
Number of subjects: 108

Group type: COMPARATOR
Intervention: tPA-induced thrombolysis alone
Number of subjects: 108
Study: 29438139

Group type: EXPERIMENTAL
Intervention: 70 kV
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: 80 kV
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: 90 kV
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 235
Study: 29438269

Group type: EXPERIMENTAL
Intervention: Stair Climbing (SC)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Non-exercising control
Number of subjects: 41
Study: 29438361

Group type: EXPERIMENTAL
Intervention: AZD0424 (5 mg to 150 mg once-daily or 40 mg bi-daily)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: AZD0424 (doses above 60 mg per day)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: AZD0424
Number of subjects: 41
Study: 29438475

Group type: EXPERIMENTAL
Intervention: T2Candida
Number of subjects: 152

Group type: COMPARATOR
Intervention: Companion cultures (cBCs)
Number of subjects: 152
Study: 29438522

Group type: EXPERIMENTAL
Intervention: Plasma RAS analysis using next-generation sequencing (NGS) and methylation digital PCR
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Plasma RAS analysis in patients with detectable ctDNA
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: NGS alone in patients with liver metastases
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: NGS plus methylated biomarkers in patients with liver metastases
Number of subjects: 425

Group type: COMPARATOR
Intervention: Absence of liver metastases
Number of subjects: 425
Study: 29438525

Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Number of subjects: 0
Study: 29438982

Group type: EXPERIMENTAL
Intervention: Circulating microRNAs
Number of subjects: 64
Study: 29439003

Group type: EXPERIMENTAL
Intervention: Dietary lifestyle factors
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Tumour necrosis factor inhibitors (TNFi)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Baseline assessments (patient-reported outcome measures, clinical assessments of disease activity, quality of life, lifestyle)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Follow-up at 14-16 weeks after treatment initiation
Number of subjects: 320
Study: 29439084

Group type: EXPERIMENTAL
Intervention: CYP1A2 activity measured after administration of caffeine
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: CYP2B6 activity measured after administration of bupropion
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: CYP2C9 activity measured after administration of tolbutamide
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: CYP2C19 activity measured after administration of omeprazole
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: CYP2D6 activity measured after administration of dextromethorphan
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: CYP2E1 activity measured after administration of chlorzoxazone
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: CYP3A4/5 activity measured after administration of midazolam
Number of subjects: 126
Study: 29439160

Group type: EXPERIMENTAL
Intervention: depression-executive dysfunction syndrome (DES)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: co-occurrence of ED and PSD
Number of subjects: 245
Study: 29439186

Group type: EXPERIMENTAL
Intervention: BGB-3111 and PD-1 antibody
Number of subjects: 0
Study: 29439670

Group type: EXPERIMENTAL
Intervention: Next-generation DNA vaccine targeting antigen-presenting cells (APCs) with a sequence encoding a chemokine (MIP-3α)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Next-generation DNA vaccine
Number of subjects: 0
Study: 29439684

Group type: EXPERIMENTAL
Intervention: PACD scores on day 1
Number of subjects: 1896

Group type: EXPERIMENTAL
Intervention: PACD scores on day 3
Number of subjects: 1896

Group type: EXPERIMENTAL
Intervention: PACD scores on day 1 for neurological patients
Number of subjects: 1896

Group type: EXPERIMENTAL
Intervention: PACD scores on day 3 for neurological patients
Number of subjects: 1896
Study: 29439707

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 427

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 427
Study: 29439857

Group type: EXPERIMENTAL
Intervention: Axitinib 5 mg orally twice per day plus pembrolizumab 2 mg/kg intravenously every 3 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 52
Study: 29439971

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400 mg/day) and Ribavirin (1,000 to 1,200 mg/day) for 3 to 52 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 30
Study: 29440006

Group type: EXPERIMENTAL
Intervention: Higher apoB/apoA-I ratio in younger patients
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Atherogenic lipid factors
Number of subjects: 159

Group type: COMPARATOR
Intervention: Older patients
Number of subjects: 159
Study: 29440043

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 592

Group type: COMPARATOR
Intervention: Medication
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: No clear preference
Number of subjects: 592
Study: 29440123

Group type: EXPERIMENTAL
Intervention: Health status outcomes including symptoms, functional status, and quality of life
Number of subjects: 1275

Group type: EXPERIMENTAL
Intervention: Follow-up assessments at 3, 6, and 12 months
Number of subjects: 1275

Group type: EXPERIMENTAL
Intervention: Clinical follow-up for PAD-related hospitalizations and major cardiovascular events
Number of subjects: 1275
Study: 29440154

Group type: EXPERIMENTAL
Intervention: Traditional surgical treatment (full sternotomy)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgical treatment
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Transcatheter surgical treatment
Number of subjects: 16
Study: 29440275

Group type: EXPERIMENTAL
Intervention: Prior PCI
Number of subjects: 3641

Group type: COMPARATOR
Intervention: Control (No prior PCI)
Number of subjects: 3641
Study: 29440404

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) for 4 weeks, intensive daily sessions.
Number of subjects: 0
Study: 29440410

Group type: EXPERIMENTAL
Intervention: Multiecho fMRI techniques
Number of subjects: 0
Study: 29440587

Group type: EXPERIMENTAL
Intervention: Single-nucleotide polymorphism (rs35705950) in mucin 5B
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29441116

Group type: EXPERIMENTAL
Intervention: Sipjeondaebo-tang (3g, 3 times a day for 4 weeks)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (3 times a day for 4 weeks)
Number of subjects: 32
Study: 29441642

Group type: EXPERIMENTAL
Intervention: Lycra splinting socks
Number of subjects: 9

Group type: COMPARATOR
Intervention: Lycra splinting shorts or leggings
Number of subjects: 9
Study: 29442437

Group type: EXPERIMENTAL
Intervention: ID3 missense variant (rs11574-A)
Number of subjects: 10359

Group type: COMPARATOR
Intervention: Control group (no genetic variant)
Number of subjects: 10359
Study: 29442440

Group type: EXPERIMENTAL
Intervention: Behavioral Treatment (BT)
Number of subjects: 0
Study: 29443701

Group type: EXPERIMENTAL
Intervention: Polypharmacy (5 or more unique medications)
Number of subjects: 266499

Group type: COMPARATOR
Intervention: No polypharmacy (fewer than 5 unique medications)
Number of subjects: 266499

Group type: EXPERIMENTAL
Intervention: Polypharmacy
Number of subjects: 266499

Group type: EXPERIMENTAL
Intervention: High-risk medications
Number of subjects: 266499

Group type: EXPERIMENTAL
Intervention: Prescriptions filled in the 30 preoperative days
Number of subjects: 266499
Study: 29444231

Group type: EXPERIMENTAL
Intervention: MOR208, 12 mg/kg intravenously, weekly for 8 weeks, with possible extension based on response.
Number of subjects: 92
Study: 29444349

Group type: EXPERIMENTAL
Intervention: Symptoms of depression and positive symptoms of psychosis (hallucinations and delusions)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Positive symptoms of psychosis (hallucinations and delusions)
Number of subjects: 404
Study: 29444530

Group type: EXPERIMENTAL
Intervention: Morphine analgesia
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control (no morphine)
Number of subjects: 300
Study: 29444644

Group type: EXPERIMENTAL
Intervention: Cooper balloon catheter (geometric volume of 2.8 ml)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Balloon pressure-volume (P-V) curves
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Estimation of Ees and calibration of Pes
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bias in bench experiment
Number of subjects: 40
Study: 29444649

Group type: EXPERIMENTAL
Intervention: Therapeutic thoracentesis (withdrawal of pleural fluid in portions of 200 ml up to 1000 ml and 100 ml above 1000 ml)
Number of subjects: 23
Study: 29444650

Group type: EXPERIMENTAL
Intervention: LPG stove with behavioral intervention (Phase 1 and Phase 2)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Behavioral intervention classes
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Home-based tailored behavioral intervention (Phase 2)
Number of subjects: 50
Study: 29444659

Group type: EXPERIMENTAL
Intervention: Right-to-left shunt (RLS) classified into four grades (Grade 0 to Grade III)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Curtain RLS
Number of subjects: 334

Group type: COMPARATOR
Intervention: No RLS
Number of subjects: 334
Study: 29444695

Group type: EXPERIMENTAL
Intervention: Manual rotation of the posterior position
Number of subjects: 238

Group type: COMPARATOR
Intervention: Expectant management with no rotation
Number of subjects: 238
Study: 29444926

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I measurement
Number of subjects: 1430

Group type: COMPARATOR
Intervention: Pretest probability determined by the CAD Consortium risk model without cardiac troponin concentrations
Number of subjects: 1430
Study: 29444998

Group type: EXPERIMENTAL
Intervention: Portico TAVI system
Number of subjects: 222
Study: 29445030

Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg orally daily until disease progression, withdrawal from study, or severe toxicity
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg orally daily
Number of subjects: 8
Study: 29445374

Group type: EXPERIMENTAL
Intervention: Familial pulmonary fibrosis (FPF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hermansky-Pudlak syndrome pulmonary fibrosis (HPSPF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unaffected relatives
Number of subjects: 0
Study: 29445400

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 3 × 400 IU
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo 3 × 1 tablets
Number of subjects: 0
Study: 29445520

Group type: EXPERIMENTAL
Intervention: AZL-M 40-mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: AZL-M 80-mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 29445521

Group type: EXPERIMENTAL
Intervention: Patient engagement event to create an educational workbook
Number of subjects: 14
Study: 29445536

Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 357
Study: 29445583

Group type: EXPERIMENTAL
Intervention: Daratumumab monotherapy
Number of subjects: 1
Study: 29445858

Group type: EXPERIMENTAL
Intervention: L-Thyroxine
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 41
Study: 29446481

Group type: EXPERIMENTAL
Intervention: hCG
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: GnRHa
Number of subjects: 261

Group type: COMPARATOR
Intervention: kisspeptin
Number of subjects: 261
Study: 29447240

Group type: EXPERIMENTAL
Intervention: Patients with severe periodontitis (SP)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Subjects without periodontitis (control group)
Number of subjects: 15
Study: 29447926

Group type: EXPERIMENTAL
Intervention: Physical activity enjoyment (PA enjoyment)
Number of subjects: 1721
Study: 29448045

Group type: EXPERIMENTAL
Intervention: Serum PIVKA-II level measured by ARCHITECT immunoassay
Number of subjects: 892
Study: 29448238

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 29448849

Group type: EXPERIMENTAL
Intervention: Small-molecule immune checkpoint inhibitors of PD-1/PD-L1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antibodies binding to PD-1 or PD-L1
Number of subjects: 0
Study: 29448936

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) administered by non-rebreather mask for up to 72 hours at 80 ppm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 0
Study: 29449135

Group type: EXPERIMENTAL
Intervention: 3 days/week before-school physical activity program
Number of subjects: 707

Group type: EXPERIMENTAL
Intervention: 2 days/week before-school physical activity program
Number of subjects: 707

Group type: COMPARATOR
Intervention: Nonparticipating children (control group)
Number of subjects: 707
Study: 29449193

Group type: EXPERIMENTAL
Intervention: Intrathecal Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) treatment
Number of subjects: 20
Study: 29449200

Group type: EXPERIMENTAL
Intervention: mHealth enabled nurse health coaching intervention (six scheduled health-coaching telephone calls, activity tracker, mobile application)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 300
Study: 29449274

Group type: COMPARATOR
Intervention: Single-vessel moderate CAD (Group 2)
Number of subjects: 1136

Group type: EXPERIMENTAL
Intervention: No apparent CAD (Group 1)
Number of subjects: 1136

Group type: EXPERIMENTAL
Intervention: Multivessel moderate CAD (Group 3)
Number of subjects: 1136

Group type: EXPERIMENTAL
Intervention: Functionally significant CAD (Group 4)
Number of subjects: 1136
Study: 29449294

Group type: EXPERIMENTAL
Intervention: Antimicrobial overtreatment regimens in patients without pseudomonal infection risk factors
Number of subjects: 5828

Group type: EXPERIMENTAL
Intervention: Clinical stability on admission
Number of subjects: 5828

Group type: EXPERIMENTAL
Intervention: Identification of definite or probable pathogen
Number of subjects: 5828

Group type: EXPERIMENTAL
Intervention: Duration from clinical stability to discharge
Number of subjects: 5828

Group type: EXPERIMENTAL
Intervention: 30-day mortality rate
Number of subjects: 5828

Group type: EXPERIMENTAL
Intervention: Low mortality risk patients with CURB-65 score 0-1
Number of subjects: 5828

Group type: EXPERIMENTAL
Intervention: Low mortality risk patients with Pneumonia Severity Index risk class I-II
Number of subjects: 5828
Study: 29449298

Group type: EXPERIMENTAL
Intervention: Smart hearing aids and a mobile phone application; a subset will also receive wearable biosensors.
Number of subjects: 1260

Group type: COMPARATOR
Intervention: Control group not specified; existing data from clinical repositories.
Number of subjects: 1260
Study: 29449367

Group type: EXPERIMENTAL
Intervention: Invasive assessment of load-independent RV contractility in HFpEF patients
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Invasive assessment of RV and left ventricular pressure-volume loops during basal conditions and handgrip exercise in HFpEF patients
Number of subjects: 24

Group type: COMPARATOR
Intervention: Invasive assessment of RV and left ventricular pressure-volume loops in control patients without heart failure symptoms
Number of subjects: 24
Study: 29449412

Group type: EXPERIMENTAL
Intervention: Asymptomatic group (NYHA class I)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Symptomatic group (NYHA class II and III)
Number of subjects: 57
Study: 29449442

Group type: EXPERIMENTAL
Intervention: Routine pressure wire assessment in all epicardial vessels of sufficient size to be amenable to revascularization
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Conventional angiography only
Number of subjects: 1100
Study: 29449879

Group type: EXPERIMENTAL
Intervention: Group Cognitive Processing Therapy (CPT)
Number of subjects: 405

Group type: COMPARATOR
Intervention: Individual support
Number of subjects: 405
Study: 29449941

Group type: EXPERIMENTAL
Intervention: High-income countries (HI)
Number of subjects: 4378

Group type: EXPERIMENTAL
Intervention: Upper-middle-income countries (UMI)
Number of subjects: 4378

Group type: EXPERIMENTAL
Intervention: Low-income countries (LI)
Number of subjects: 4378

Group type: EXPERIMENTAL
Intervention: All national income groups
Number of subjects: 4378